Journey Medical (US:DERM) ZACKS·2025-11-12 23:15Core Insights - Journey Medical Corporation reported a quarterly loss of $0.09 per share, slightly worse than the Zacks Consensus Estimate of a loss of $0.08, but an improvement from a loss of $0.12 per share a year ago, indicating a -12.50% earnings surprise [1] - The company generated revenues of $17.63 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 0.39%, but showing growth from $14.63 million in the same quarter last year [2] - Journey Medical shares have increased approximately 131.5% year-to-date, significantly outperforming the S&P 500's gain of 16.4% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.03 on revenues of $19.5 million, and for the current fiscal year, it is -$0.42 on revenues of $68.15 million [7] - The estimate revisions trend for Journey Medical was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6] Industry Context - The Medical - Drugs industry, to which Journey Medical belongs, is currently ranked in the top 32% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]